Research update
State-of-the-Art Embryo Selection for $4,999
Stronger genetic prediction. Validation within families. Clearer information for your next IVF decision.
Reticular Team
October 2026 · 6 minute read
Today, we’re sharing the technical whitepaper behind Embryo Complete, our polygenic embryo selection product. Embryo Complete is available for a flat $4,999 for all your embryos, across every cycle. We use compatible data from your existing PGT-A testing, requiring no additional embryo biopsy.
Our latest evaluation covers 14 heritable conditions, including multiple sclerosis, breast cancer, and type 2 diabetes. We’re sharing what these models predict, how they compare with published scores, and how we test whether their signal holds when comparing people within the same family.
What could this mean for your family?
Using our latest prediction results, we estimate a relative risk reduction of up to 63% when selecting the lowest-risk embryo from five sibling embryos capable of live birth. The largest modeled reduction in this comparison is for multiple sclerosis.
Relative risk reduction describes the proportional change in risk. Absolute risk reduction describes how far the risk falls in percentage points.
How much could risk fall?
Relative risk reduction (%) · Five embryos
Multiple sclerosis
Inflammatory bowel disease
Alzheimer's disease
Glaucoma
Prostate cancer
Gout
Psoriasis
Melanoma
Type 2 diabetes
Breast cancer
Basal cell carcinoma
Hypertension
Osteoporosis
These are model estimates based on selecting for one condition at a time. They assume five embryos could each yield a live birth; fewer viable options, transfer failure, ancestry, and model performance can change the expected benefit.
When a condition runs in your family
Family history can raise a child’s lifetime risk. For families with a higher starting risk, embryo selection may offer a larger absolute reduction in the chance of developing that condition.
Type 2 diabetes: what our model estimates
When selecting the embryo with the lowest predicted diabetes risk from five sibling embryos, our model estimates:
With one affected parent, lifetime risk falls from 30.7% to 18.0%. That is a 41.2% relative reduction, or 12.6 percentage points.
With two affected parents, lifetime risk falls from 57.2% to 41.4%. That is a 27.6% relative reduction, or 15.8 percentage points.
Explore the figure below to see how family history changes the estimates for each condition. Switch between relative reduction and absolute risk to compare the percentage reduction with the starting risk and the reduction in percentage points.
Risk reduction with family history
Relative risk reduction (%) · Five embryos
Alzheimer's disease
Type 2 diabetes
Prostate cancer
Glaucoma*
Inflammatory bowel disease
Basal cell carcinoma*
Gout*
Testicular cancer*
Breast cancer
Hypertension
Multiple sclerosis
Psoriasis
Melanoma
Osteoporosis
Prediction on par with leading published scores
Our prediction results have improved substantially. In the comparison below, Reticular’s estimates are comparable to or higher than published estimates for 12 of 14 conditions, with particularly strong results for glaucoma, inflammatory bowel disease, and multiple sclerosis.
The figure measures liability R²: how much variation in the underlying risk of a condition a score explains. Higher values indicate stronger prediction. It is a measure of model performance, rather than a percentage reduction in someone’s chance of developing a condition.
Prediction across 14 conditions
Liability R² (%) · Reticular and published scores
Alzheimer's disease
Type 2 diabetes
Prostate cancer
Glaucoma
Inflammatory bowel disease
Basal cell carcinoma
Gout
Testicular cancer
Breast cancer
Hypertension
Multiple sclerosis
Psoriasis
Melanoma
Osteoporosis
Testing across ancestry groups
Families come from many genetic backgrounds. A score that predicts well in one population needs to be evaluated in others before we assume the same performance.
We examine prediction across ancestry groups in All of Us. The results support predictive signal across several conditions and populations, while also showing that performance varies by condition and ancestry. Smaller case counts make some estimates less precise. Those differences matter when interpreting a family’s report.
Prediction across ancestry groups
AUC-derived liability R² (%) · External-permitted scores
Alzheimer's disease
Type 2 diabetes
Prostate cancer
Glaucoma
Inflammatory bowel disease
Basal cell carcinoma
Gout
Breast cancer
Hypertension
Multiple sclerosis
Psoriasis
Melanoma
Osteoporosis
Validation that compares people within families
Embryo selection compares siblings. Within-family validation therefore asks a crucial question: does a genetic score still distinguish risk when shared ancestry and family background are controlled for?
For 11 of the 12 conditions with interpretable within-family estimates, we found no detectable attenuation of the predictive signal. Type 2 diabetes showed some attenuation, with a within-family-to-population effect ratio of about 0.86. Alzheimer’s disease and testicular cancer estimates were unstable because there were too few cases for reliable interpretation.
Does prediction hold within families?
Within-family / population effect · Ratio
Type 2 diabetes
Multiple sclerosis
Hypertension
Psoriasis
Glaucoma
Osteoporosis
Basal cell carcinoma
Breast cancer
Gout
Prostate cancer
Inflammatory bowel disease
Melanoma
Alzheimer's disease
Testicular cancer
Parental genetic data are limited in our All of Us sample. Once our access to UK Biobank is restored, we expect to strengthen our within-family validation and improve the precision of these estimates.
Better information for planning your family
We’re continuing to improve genetic prediction and the evidence behind it. Stronger scores, evaluation across ancestry groups, and validation within families all help us build a clearer picture of what an embryo’s genome can tell us.
Our goal is to give families useful information they can discuss with their IVF team and genetic counselor. We’re excited to keep advancing that work—and to share the methods and results behind it.
Explore Embryo Complete
A flat $4,999 for all embryos, across all cycles. Compatible existing PGT-A data. No additional embryo biopsy. Genetic counseling included.
Sources and further reading
- Reticular technical whitepaper, October 2026 ↗
- Lencz et al., Utility of polygenic embryo screening, 2021 ↗
- PEStimate: predicting offspring disease risk, 2026 ↗
Modeled disease risks are probabilistic estimates. Genetic scores do not guarantee a health outcome; IVF decisions should also account for the clinical information provided by your care team.